Insider · CIK 0001110744
Fred Hassan
director
Files at EYPT (EyePoint, Inc.), PGEN (PRECIGEN, INC.), COCP (Cocrystal Pharma, Inc.), BBIO (BridgeBio Pharma, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | PGEN PRECIGEN, INC. | MOption exercise Common Stock | +71,839 | - | - | 1,243,239 | Mar 16, 2026 |
| Mar 13, 2026 | PGEN PRECIGEN, INC. | MOption exercise Restricted Stock Unitsderivative | -71,839 | $0.00 | $0 | 0 | Mar 16, 2026 |
| Mar 10, 2026 | PGEN PRECIGEN, INC. | AGrant or award Common Stock | +17,948 | $3.51 | $63k | 1,171,400 | Mar 12, 2026 |
| Mar 10, 2026 | PGEN PRECIGEN, INC. | AGrant or award Restricted Stock Unitsderivative | +35,612 | $0.00 | $0 | 35,612 | Mar 12, 2026 |
| Mar 10, 2026 | PGEN PRECIGEN, INC. | AGrant or award Option to Purchase Common Stock (Right to Buy)derivative | +41,073 | $0.00 | $0 | 41,073 | Mar 12, 2026 |
| Jan 9, 2026 | COCP Cocrystal Pharma, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +16,410 | $0.00 | $0 | 16,410 | Jan 13, 2026 |
| Jan 2, 2026 | EYPT EyePoint, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 6, 2026 |
| Oct 28, 2025 | COCP Cocrystal Pharma, Inc. | AGrant or award Common Stock | +359,713 | $1.39 | $500k | 1,383,009 | Oct 30, 2025 |
| Oct 28, 2025 | COCP Cocrystal Pharma, Inc. | AGrant or award Warrantsderivative | +719,426 | $1.39 | $1.0M | 719,426 | Oct 30, 2025 |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | AGrant or award Common Stock | +6,589 | $0.00 | $0 | 25,889 | Jun 24, 2025 |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,425 | $0.00 | $0 | 8,425 | Jun 24, 2025 |
| Mar 13, 2025 | PGEN PRECIGEN, INC. | AGrant or award Common Stock | +36,206 | $1.74 | $63k | 1,066,040 | Mar 17, 2025 |
| Mar 14, 2025 | PGEN PRECIGEN, INC. | MOption exercise Common Stock | +87,412 | - | - | 1,153,452 | Mar 17, 2025 |
| Mar 13, 2025 | PGEN PRECIGEN, INC. | AGrant or award Restricted Stock Unitsderivative | +71,839 | $0.00 | $0 | 71,839 | Mar 17, 2025 |
| Mar 14, 2025 | PGEN PRECIGEN, INC. | MOption exercise Restricted Stock Unitsderivative | -87,412 | $0.00 | $0 | 0 | Mar 17, 2025 |
| Mar 13, 2025 | PGEN PRECIGEN, INC. | AGrant or award Option to Purchase Common Stock (Right to Buy)derivative | +83,517 | $0.00 | $0 | 83,517 | Mar 17, 2025 |
| Jan 3, 2025 | EYPT EyePoint, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 7, 2025 |
| Oct 9, 2024 | COCP Cocrystal Pharma, Inc. | AGrant or award Common Stock | +8,067 | - | - | 1,023,296 | Oct 11, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.